Endothelial Nitric Oxide Synthase (NOS3) Polymorphisms in African Americans With Heart Failure: Results From the A-HeFT Trial

Journal of Cardiac Failure

Volumn 15, Issue 3, 2009, Pages 191-198

  McNamara, Dennis M ^a   Tam, S William ^b   Sabolinski, Michael L ^b   Tobelmann, Page ^a   Janosko, Karen ^a   Venkitachalam, Lakshmi ^a   Ofili, Elizabeth ^c   Yancy, Clyde ^d   Feldman, Arthur M ^e   Ghali, Jalal K ^f   Taylor, Anne L ^g   Cohn, Jay N ^h   Worcel, Manuel ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NitroMed Inc   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NewYork Presbyterian Hospital   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

Author keywords

isosorbide dinitrate and hydralazine; left ventricular ejection fraction; nitric oxide; Pharmacogenetics

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRALAZINE; ISOSORBIDE DINITRATE;

AFRICAN AMERICAN; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

AFRICAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; DIASTOLE; DRUG COMBINATIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HEART FAILURE; HUMANS; HYDRALAZINE; INTRONS; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; STROKE VOLUME; VASODILATOR AGENTS;

EID: 62649122885     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.10.028     Document Type: Article

References (37)

1. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314 (1986) 1547-1552
2. Carson P., Ziesche S., Johnson G., and Cohn J.N. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5 (1999) 178-187
3. Cohn J.N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
4. Taylor A.L. The African-American Heart Failure Trial (A-HeFT): rationale and methodology. J Card Fail 9 5 Suppl Nitric Oxide (2003) S216-S219
5. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino Jr. R., Ferdinand K., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
6. Angus D.C., Linde-Zwirble W.T., Tam S.W., Ghali J.K., Sabolinski M.L., Villagra V.G., et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation 112 (2005) 3745-3753
7. Kojda G., and Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res 41 (1999) 514-523
8. Drexler H. Nitric oxide synthases in the failing human heart: a double-edged sword?. Circulation 99 (1999) 2972-2975
9. Heymes C., Vanderheyden M., Bronzwaer J.G.F., Shah A.M., and Paulus W.J. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 99 (1999) 3009-3016
10. Kelly R.A., Balligand J.L., and Smith T.W. Nitric oxide and cardiac function. Circ Res 79 (1996) 3
11. Wang X.L., Mahaney M.C., Sim A.S., Wang J., Wang J., Blangero J., et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler Thromb Vasc Biol 17 (1997) 3147-3153
12. Marsden P.A., Heng H.H., Scherer S.W., Stewart R.J., Hall A.V., Shi X.M., et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 268 (1993) 17478-17488
13. Wattanapitayakul S.K., Mihm M.J., Young A.P., and Bauer J.A. Therapeutic implications of human endothelial nitric oxide synthase gene polymorphism. Trends Pharmacol Sci 22 (2001) 361-367
14. Metzger I.F., Souza-Costa D.C., Marroni A.S., Nagassaki S., Desta Z., Flockhart D.A., et al. Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genom 15 (2005) 565-570
15. Jáchymová M., Horký K., Bultas J., Kozich V., Jindra A., Peleska J., et al. Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun 284 (2001) 426-430
16. Czarnecka D., Kawecka-Jaszcz K., Stolarz K., Olszanecka A., Dembińska-Kieć A., and Kieć-Wilk B. Ambulatory blood pressure, left ventricular mass and vascular phenotypes in relation to the endothelial nitric oxide synthase gene Glu298Asp and intron 4 polymorphisms in a population-based family study. J Human Hypertens 19 (2005) 413-420
17. 298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation 100 (1999) 1515-1520
18. Nassar B.A., Bevin L.D., Johnstone D.E., O'neill B.J., Bata I.R., Kirkland S.A., et al. Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease. Am Heart J 142 (2001) 586-589
19. 298 variant of endothelial nitric oxide synthase: effect on survival for patients with congestive heart failure. Circulation 107 (2003) 1598-1602
20. Taylor J.S., and Ellis G.R. Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure. Am J Cardiovasc Drugs 2 (2002) 389-399
21. Tanus-Santos J.E., Desai M., and Flockhart D.A. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 11 (2001) 719-725
22. McNamara D.M., Holubkov R., Postava L., Janosko K., MacGowan G.A., Mathier M., et al. Pharmacogenetic interactions between ACE inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 44 (2004) 2019-2026
23. Cohn J.N., Tam S.W., Anand I.S., Taylor A.L., Sabolinski M.L., Worcel M., and Investigators A.-H. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail 13 (2007) 331-339
24. Marroni A.S., Metzger I.F., Souza-Costa D.C., Nagassaki S., Sandrim V.C., Correa R.X., et al. Consistent interethnic difference in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide 12 (2005) 177-182
25. Zhu H., Wang X., Dong Y., Treiber F.A., and Sniederet H. Influence of the eNOS gene on development of blood pressure and left ventricular mass: longitudinal findings in multiethnic youth. Pharmacogenet Genom 15 (2005) 669-675
26. Tesauro M., Thompson W.C., Rogliani P., et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. PNAS 97 (2000) 2832-2835
27. Nakayama M., Yasue H., Yoshimura M., et al. T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99 (1999) 2864-2870
28. Wang J., Dudley D., and Wang X.L. Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler Thromb Vasc Biol 22 (2002) e1-e4
29. Zhu H., Wang X., Dong Y., Treiber F.A., and Snieder H. Influence of the eNOS gene on development of blood pressure and left ventricular mass: longitudinal findings in multiethnic youth. Pharmacogenet Genom 15 (2005) 669-675
30. Nejatizadeh A., Kumar R., Stobdan T., Goyal A.K., Sikdar S., Gupta M., et al. Endothelial nitric oxide synthase gene haplotypes and circulating nitric oxide levels significantly associate with risk of essential hypertension. Free Radic Biol Med 44 (2008) 1912-1918
31. Scherrer-Crosbie M., Ullrich R., Bloch K.D., Nakajima H., Nasseri B., Aretz H.T., et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 104 (2001) 1286-1291
32. Yang X.P., Liu Y.H., Shesely E.G., Bulagannawar M., Liu F., and Carretero O.A. Endothelial nitric oxide gene knockout mice cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension 34 (1999) 24-30
33. Stein B., Frank P., Schmitz W., Scholz H., and Thoenes M. Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol 28 (1996) 1631-1639
34. Shinke T., Takaoka H., Takeuchi M., Hata K., Kawai H., Okubo H., et al. Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to β-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy. Circulation 101 (2000) 1925-1930
35. Yamamoto S., Tsutsui H., Tagawa H., Saito K., Takahashi M., Tada H., et al. Role of myocyte nitric oxide in beta-adrenergic hyporesponsiveness in heart failure. Circulation 95 (1997) 1111-1114
36. Hare J.M. Stamler JS NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 115 (2005) 509-517
37. Hare J.M. Nitroso-redox balance in the cardiovascular system. N Engl J Med 351 (2004) 2112-2114